DTYMK and cancer: We noticed that DTYMK expression was the lowest in C3 subtypes (inflammatory, high Th1 and Th17 infiltration) of human cancers, especially in BLCA, BRCA, ESCA, LUAD, LUSC, OV, PAAD, prostate adenocarcinoma (PRAD), READ, SARC, and STAD.